Leading CBD Investor In London Developing Cannabis Genetics For Healthcare With Swiss Grower

The power of CBD as medicine has long been a focus of researchers and growers. It’s been documented both anecdotally and through a number of significant studies.

But a new partnership between the Swiss developer of one of the world’s most popular CBD strains and a London-based investor aims to target specific ailments with hyper-focused hemp products.

Bio Zu Farm, based in Sant’Antonino near Switzerland’s border with Italy, and London-based Swiss Life Sciences said Monday the two companies are working together to develop proprietary strains of cannabis to treat a variety of specific illnesses and diseases, including epilepsy, autism and the different variants of COVID-19.

The pair of companies hope to develop genetics match the terpene profiles, THC levels and CBD levels already being used in treatments and improve on them with new crops containing more consistent genetics.

Matteo Ambrosini, Bio Zu Farm’s chief operating officer, said the partnership formed from a shared desire to develop cannabis genetics “from the ground up.”

“(Swiss Life Sciences) is helping us take close attention to detail to make sure that we will be at the cutting edge of the industry,” Ambrosini said in a statement.

Bio Zu Farm is best known for its BZ1 hemp flower, one of Europe’s most popular cannabis strains that’s consumed by millions of consumers across the world. BZ1 is a relaxing Indica-dominant strain that claims to produce a calming effect for its users and help them sleep. Its strong aroma of pineapple and caramel produces a sweet, buttery flavor with a slight mint aftertaste.

Bio Zu Farm markets the strain as an agent to assuage anxiety and pain as well as nausea, migraines, insomnia and fatigue.

The company is also managing the set-up and operation of Swiss Life Sciences’ state-of-the-art production facility in Switzerland, which uses the latest propagation systems and blockchain tech to market pharmaceutical-grade CBD products for the healthcare and medical industries.

JP Engele, COO of a Swiss Life Science subsidiary named Savim SA, said the company chose to work with Bio Zu Farm after two years of seeking an ideal partner to help grow “life-changing” cannabis strains. The group aims to make their new strains, set to hit the market in the coming weeks, globally available in legal cannabis markets.